Cat. #161759
OvsahoCarbo Cell Line
Cat. #: 161759
Organism: Human
Tissue: Ovary
Model: Mutant
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Michelle Lockley
Institute: Queen Mary University of London, UK.
Primary Citation: J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: OvsahoCarbo Cell Line
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Parental cell: Ovsaho cell line
- Organism: Human
- Gender: Female
- Tissue: Ovary
- Growth properties: Adherent
- Model: Mutant
- Model description: Platinum-resistant HGSC in vivo cell line
- Crispr: No
- Description: Platinum-resistant HGSC cancer cells with a growth advantage in the presence of therapy that expand to create drug-resistant tumours.
- Production details: Cells were cultured in vitro in increasing concentrations of either cisplatin or carboplatin until an increase in IC50 between two and ten-fold was achieved to reflect the resistance observed in human patients
Handling
- Growth medium: RPMI containing 10% FBS and 1% penicillin/streptomycin. Cells should be cultured without drug but used at low passage to ensure drug resistance is maintained.
- Temperature: 37° C
- Cultured in antibiotics: Streptomycin and Penicillin
- Mycoplasma free: Yes
- Str profiling: 16 locus STR verification (DNA Diagnostics Centre, London, UK: June 2015?February 2016 and European Collection of Authenticated Cell Lines August 2019)
References
- J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.
